A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

NCT06906900 | Recruiting Phase 1 DMC FDA Device

• 2 other identifiers: 2024-1879NCI-2025-02319
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.

Conditions

Spinal Metastasis

Outcome Measures

Primary Outcomes (1)

• Safety and Adverse Events (AEs)

  Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

  Through study completion; an average of 1 year

Study Arms (1)

Treatment with 150 KHZ (NovoTTF-200M) or 200KHZ (NovoTTF-200A)

EXPERIMENTAL

Device: TTF-200M and TTF-200A systems

Interventions

TTF-200M and TTF-200A systems DEVICE

Participants will receive treatment with NovoTTF-200M or NovoTTF-200A and treatment will continue as long as the doctor thinks it is in the participant's best interest.

Treatment with 150 KHZ (NovoTTF-200M) or 200KHZ (NovoTTF-200A)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with one or more spinal metastasis(es) affecting levels between C1 to S4 which have been previously treated with surgery and/or maximal doses radiation therapy to the spinal metastasis. For patients in the surgical group, patients must have completed maximal intralesional debulking of their tumor (within 90 days of enrollment).
• No more radiation options available for treatment to the spinal metastasis(es) that will undergo the TTF treatment
• Male or Female subjects aged ≥ 22 years.
• Women of child-bearing potential (women who are not postmenopausal for at least one year or are not surgically sterile) must agree prior to study entry to use adequate contraception (e.g., hormonal, barrier device, or abstinence) for the duration of study participation.
• Patients must have a Karnofsky Performance Scale (KPS) (Appendix D) score of at least 70%.
• Patients must have the ability to independently disconnect the arrays or turn off the system if they feel uncomfortably hot while using the device.
• Patients (and/or legally authorized representative) should be able to fully understand the requirements of the trial, including the need to use the device for at least 18 hours per day, be willing to comply with all trial visits and assessments and be willing and able to sign an Institutional Review Board (IRB) approved written informed consent document (or provide assent where applicable).
• Patients with the following tumor histologies (numbers in parenthesis represent the frequencies/device patients with these histologies will be treated with):
• Non-small cell lung cancer (150KHZ, TTF-200M)
• Chordoma (150KHZ, TTF-200M)
• Breast adenocarcinoma (150HKZ, TTF-200M)
• Liver/gastrointestinal malignancy (150 KHZ, TTF-200M)
• Endocrine origin carcinoma (150KHZ, TTF-200M)
• Renal cell carcinoma (200KHZ, TTF-200A)
• Prostate adenocarcinoma (200KHZ, TTF-200A)

You may not qualify if:

• Psychiatric illness/social situations (homeless or living in a foreign country) that would limit compliance with study requirements.
• Physical or cognitive limitation that prevents the ability to independently disconnect the arrays or turn off the system if they feel uncomfortably hot while using the device. This includes patients that need a legally authorized representative for consent.
• Patients in the surgery group who have not fully recovered from the spinal surgery, where wound healing is compromised, requiring healing by second intention (i.e., the wound is left open and heals spontaneously).
• History of allergic reactions or sensitivity to conductive hydrogels used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.
• Implanted pacemaker, defibrillator, nerve stimulator or other active electronic medical devices in the area of surgery or application of the skin transducers.
• Women who are pregnant or lactating.
• Patients with leptomeningeal disease.
• Patients with severe pre-existing dermatological conditions (i.e., active herpes zoster, bullous pemphigoid reactions, Stevens-Johnson syndrome) that might interfere with interpretation of the device's skin toxicity.
• Multiple noncontiguous progressive spine tumors separated by more than 25 cm.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead
• NovoCure Ltd.: collaborator

Study Sites (1)

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

• MD Anderson Cancer Center Website

Study Officials

• Claudio Tatsui, MD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Claudio Tatsui, MD

CONTACT

(713) 563-8710; cetatsui@mdanderson.org

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 26, 2025
• First Posted: April 2, 2025
• Study Start: August 18, 2025
• Primary Completion (Estimated): February 17, 2027
• Study Completion (Estimated): February 17, 2029
• Last Updated: April 20, 2026

Record last verified: 2026-04

Locations

US (1)